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(71.2%) followed by cost of hospital stay (21.8%) and diag-
nostic costs (7%). Costs of hospital care for patients with ven-
tricular arrhythmias were signiﬁcantly higher as compared to
patients with heart failure (€5890.82 and €1959.35, respec-
tively). CONCLUSIONS: This study demonstrates that ARVC is
associated with high hospitalization costs in Poland, mainly due
to large costs of antiarrhythmic procedures.
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OBJECTIVES: To investigate different scenarios of warfarin
treatment for patients with non-valvular atrial ﬁbrillation who
are eligible to receive anticoagulation for stroke prevention. Sce-
narios include different proportions of eligible patients being
treated, as well as the level of anticoagulation obtained (i.e.
within and outside the recommended INR range). METHODS:
A decision-analytical model was constructed from a third party
payer perspective for the US. The model runs for ﬁve years in
yearly cycles. Strokes (fatal, major, minor and no deﬁcit) and
bleeding events (fatal, intracranial, major and minor) were
modeled. Probabilities and costs associated with events were
taken from published sources. Four scenarios were compared:
1). 100% of eligible patients warfarin treated and all within the
therapeutic range; 2). 100% of eligible patients’ warfarin treated
whereof 67% within and 33% outside the therapeutic range
(randomized controlled trial-like); 3). 100% of eligible patients
warfarin treated whereof 50% within/outside the therapeutic
range (routine practice INR levels); and 4). 55% warfarin treated
(of whom 50% within/outside recommended INR range), 5% no
treatment, and 40% aspirin (routine practice for warfarin treat-
ment rates and INR levels). RESULTS: At 5 years, total costs per
patient (discounted at 3%) and the total number of strokes per
1000 patients (discounted at 3%) were for strategy 1: $8607 and
25, for strategy 2: $12,518 and 46, for strategy 3: $14,582 and
58, and for strategy 4: $15,480 and 129, respectively. CON-
CLUSIONS: In a real world setting, evidence demonstrates that
patient’s eligible for anticoagulation may not be treated, and
those treated with warfarin may not be in the therapeutic range
for anticoagulation. This will lead to marked differences between
the observed efﬁcacy and effectiveness as demonstrated for the
number of strokes and costs in this model. This will need to be
addressed in any cost-effectiveness analysis using warfarin as
comparator.
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OBJECTIVES: Describe prevalence and characteristics of
patients with chronic nonvalvular atrial ﬁbrillation (NVAF) and
≥1 risk factor (RF) for thromboembolism in France in 2004, and
document reasons for vitamin K antagonists (VKA) underuse 
in those patients for whom anticoagulation is indicated.
METHODS: Cross sectional study. All patients with arrhythmia
or AF presenting to cardiologists (n = 43) from the THALES
observatory during a 3-month period were evaluated via ques-
tionnaire. Statistical comparisons were by chi2 and ANOVA
analyses. Data were extrapolated using the THALES database to
give representative national values. RESULTS: 409 patients met
the inclusion criteria, i.e., conﬁrmed NVAF and ≥1 thromboem-
bolic RF (mean age 76 years; mean number of thromboembolic
RF 2.11; 58.7% male). Of these, 37.2% had 1 RF, 28.9% had
2 RF and 34.0% had ≥3 RF. VKA was prescribed to 65.5% of
patients. VKA treatment was associated with a higher mean
number of RF (2.28) than aspirin (2.20) or no treatment (1.61).
Among VKA-treated patients, 18.6% were judged difﬁcult to
stabilise/not stabilised by the physician. Main reasons for not
prescribing VKA were insufﬁcient risk: beneﬁt (37.6%), patient’s
refusal due to VKA restrictions (23.4%) and patient’s inherent
haemorrhagic risk (19.1%). According to anticoagulation exclu-
sion criteria (severe hepatic insufﬁciency, recent stroke, and
patient’s inherent haemorrhagic risk) most patients not treated
with VKA (77.3%) would have been eligible for anticoagulation.
Extrapolation of these ﬁndings to the French population equated
to 426,731 (95% CI 420,099–433,363) patients with chronic
NVAF. Of these, 147,124 (34.5%) would not be treated with
VKA, even though 113,719 would have been eligible for anti-
coagulation. CONCLUSIONS: These data suggest that one 
third of French patients with chronic NVAF and ≥1 throm-
boembolic RF presenting to cardiologists are currently not
treated with VKA. Main drivers for this non-prescription are
more related to risk and constraints of VKA treatment than
formal contraindications.
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OBJECTIVES: To determine the proportion of patients with
non-valvular atrial ﬁbrillation (NVAF) treated with warfarin that
achieved INR stability. To then evaluate the associations between
stability and outcome, and factors that predict stability.
METHODS: A retrospective record linkage study in 1513
patients with NVAF treated with warfarin for a minimum of six
months. The setting was a large UK population (ª450,000
people). The main outcome measures were stability deﬁned as
six consecutive months within the target INR range (2.0–3.0),
thromboembolic and bleeding event rates, and mortality. Sec-
ondary outcome measures included the predictive value of base-
line characteristics and other treatment variables. RESULTS:
Stability was achieved in 52% of the study group. Standardised
mean survival was signiﬁcantly higher in the group who achieved
stability (D = 16.9 months, p < 0.001) with a hazard ratio of 4.36
(p < 0.001). The stable group had a lower rate of both throm-
boembolic events (0.8% vs. 2.3% per patient year) and major
bleeds (0.4% vs. 1.2% per patient year). Failure to achieve 
stability was associated with age (odds ratio 1.01 (95% CI
1.001–1.021)) and morbidity at baseline (OR 1.015; 95% CI
1.007–1.022). Greater variability in INR was also associated
with a failure to achieve stability (OR 1.518; 95% CI
1.427–1.615). Receiver operator characteristic (ROC) analysis
using data from the ﬁrst three month of treatment demonstrated
good discrimination of stability using age and morbidity at base-
line and percent time in range and frequency of visits during ﬁrst
three months treatment (AUC 0.780; SE 0.012; 95% CI
0.757–0.803). CONCLUSIONS: Many patients never achieved
